BOXED O
WARNING O
: O
WARNING O
: O
DIMINISHED O
ANTIPLATELET O
EFFECT O
IN O
PATIENTS O
WITH O
TWO O
LOSS-OF-FUNCTION O
ALLELES O
OF O
THE O
CYP2C19 O
GENE O
WARNING O
: O
DIMINISHED O
ANTIPLATELET O
EFFECT O
IN O
PATIENTS O
WITH O
TWO O
LOSS-OF-FUNCTION O
ALLELES O
OF O
THE O
CYP2C19 O
GENE O
EXCERPT O
: O
WARNING O
: O
DIMINISHED O
ANTIPLATELET O
EFFECT O
IN O
PATIENTS O
WITH O
TWO O
LOSS-OF-FUNCTION O
ALLELES O
OF O
THE O
CYP2C19 O
GENE O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Effectiveness O
of O
Plavix O
depends O
on O
conversion O
to O
an O
active O
metabolite O
by O
the O
cytochrome O
P450 O
( O
CYP O
) O
system O
, O
principally O
CYP2C19 O
. O

( O
5.1 O
, O
12.3 O
) O
* O
Tests O
are O
available O
to O
identify O
patients O
who O
are O
CYP2C19 O
poor O
metabolizers O
. O

( O
12.5 O
) O
* O
Consider O
use O
of O
another O
platelet O
P2Y12 O
inhibitor O
in O
patients O
identified O
as O
CYP2C19 O
poor O
metabolizers O
. O

( O
5.1 O
) O
The O
effectiveness O
of O
Plavix O
results O
from O
its O
antiplatelet O
activity O
, O
which O
is O
dependent O
on O
its O
conversion O
to O
an O
active O
metabolite O
by O
the O
cytochrome O
P450 O
( O
CYP O
) O
system O
, O
principally O
CYP2C19 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Plavix O
at O
recommended O
doses O
forms O
less O
of O
the O
active O
metabolite O
and O
so O
has O
a O
reduced B-NonOSE_AE
effect I-NonOSE_AE
on I-NonOSE_AE
platelet I-NonOSE_AE
activity I-NonOSE_AE
in O
patients O
who O
are O
homozygous B-Not_AE_Candidate
for I-Not_AE_Candidate
nonfunctional I-Not_AE_Candidate
alleles I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
CYP I-Not_AE_Candidate
2 I-Not_AE_Candidate
C I-Not_AE_Candidate
1 I-Not_AE_Candidate
9 I-Not_AE_Candidate
gene I-Not_AE_Candidate
, O
( O
termed O
" B-Not_AE_Candidate
CYP I-Not_AE_Candidate
2 I-Not_AE_Candidate
C I-Not_AE_Candidate
1 I-Not_AE_Candidate
9 I-Not_AE_Candidate
poor I-Not_AE_Candidate
metabolizers I-Not_AE_Candidate
" I-Not_AE_Candidate
) O
. O

Tests O
are O
available O
to O
identify O
patients O
who O
are O
CYP2C19 O
poor O
metabolizers O
[ O
see O
Clinical O
Pharmacology O
( O
12.5 O
) O
] O
. O

Consider O
use O
of O
another O
platelet O
P2Y12 O
inhibitor O
in O
patients O
identified O
as O
CYP2C19 O
poor O
metabolizers O
. O

